LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Lista de Ações・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Fechado

SetorSaúde

21.45 -0.23

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

21.45

Máximo

21.45

Indicadores-chave
By Trading Economics
Rendimento	-1.6M -21M
Vendas	14M 54M
Margem de lucro	-39.611
Funcionários	178
EBITDA	-3.8M -23M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	-3.62% downside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	1B 2.2B
Abertura anterior	21.68
Fecho anterior	21.45

Sentimento de Notícias

By Acuity

50%

162 / 346 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

6.26 / 7.47 Suporte e Resistência

Day One Biopharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de mai. de 2026, 22:54 UTC

Ganhos

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 de mai. de 2026, 23:51 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 de mai. de 2026, 23:51 UTC

Conversa de Mercado

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

13 de mai. de 2026, 23:17 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 de mai. de 2026, 23:16 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 de mai. de 2026, 23:15 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 de mai. de 2026, 23:14 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 de mai. de 2026, 23:02 UTC

Conversa de Mercado

Ganhos

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 de mai. de 2026, 22:59 UTC

Conversa de Mercado

Ganhos

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 de mai. de 2026, 22:24 UTC

Ganhos

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 de mai. de 2026, 22:23 UTC

Ganhos

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 de mai. de 2026, 22:23 UTC

Ganhos

Xero FY International Revenue Growth 47%>XRO.AU

13 de mai. de 2026, 22:22 UTC

Ganhos

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 de mai. de 2026, 22:19 UTC

Ganhos

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 de mai. de 2026, 22:19 UTC

Ganhos

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 de mai. de 2026, 22:18 UTC

Ganhos

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 de mai. de 2026, 22:16 UTC

Ganhos

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 de mai. de 2026, 22:15 UTC

Ganhos

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 de mai. de 2026, 22:15 UTC

Ganhos

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 de mai. de 2026, 22:13 UTC

Ganhos

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 de mai. de 2026, 22:12 UTC

Ganhos

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 de mai. de 2026, 22:11 UTC

Ganhos

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 de mai. de 2026, 22:11 UTC

Ganhos

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 de mai. de 2026, 22:10 UTC

Ganhos

Xero Did Not Declare a Dividend>XRO.AU

13 de mai. de 2026, 22:10 UTC

Ganhos

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 de mai. de 2026, 22:09 UTC

Ganhos

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 de mai. de 2026, 22:00 UTC

Ganhos

Cisco to Shed Jobs for All-In AI Push -- Update

13 de mai. de 2026, 21:11 UTC

Ganhos

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Comparação entre Pares

Variação de preço

Day One Biopharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

-3.62% parte inferior

Previsão para 12 meses

Média 20.75 USD -3.62%

Máximo 21.5 USD

Mínimo 17 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Day One Biopharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

7 ratings

Comprar

Manter

Vender

Com base em 7 analistas que deram avaliações de ações para Day One Biopharmaceuticals Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

6.26 / 7.47Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentimento

By Acuity

162 / 346 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.